tbuckley/cabot-search huggingface dataset:
Good Tolerance of Lenalidomide Maintenance Therapy in Patients with High Risk Profile Chronic Lymphocytic Leukemia (CLL) after Frontline Chemoimmunotherapy: Preliminary Safety Overview of the CLLM1 Trial of the German CLL Study Group (GCLLSG)
Authors: Barbara Eichhorst, Jasmin Bahlo, Anna Maria Fink, Michael Pfreundschuh, Holger Hebart, Georg Maschmeyer, Kathleen Jentsch-Ulrich, Steffen Dörfel, Anne Westermann, Aline Zey, Kirsten Fischer, Clemens-Martin Wendtner, Thomas Noesslinger, Paolo Ghia, Francesc Bosch, Arnon P. Kater, Karl-Anton Kreuzer, Hartmut Döhner, Stephan Stilgenbauer, Sebastian Boettcher, Michael Hallek
Journal: Blood (2014)
Safety and efficacy of anti-PD-1 inhibitor ABBV-181 in lung and head and neck carcinoma
Authors: A. Italiano, P. Cassier, D. Roda, C.-C. Lin, K. Peltola, A. Gazzah, H.-S. Shiah, E. Calvo, D. Tosi, B. Gao, L. warburton, M. Tanner, S. Englert, S. Lambert, A. Parikh, D. Afar, G. Vosganian, V. Moreno
Journal: Annals of Oncology (2019)
Prior tyrosine kinase inhibitors (TKI) and antibiotics (ATB) use are associated with distinct gut microbiota ‘guilds’ in renal cell carcinoma (RCC) patients
Authors: V. Iebba, L. Albiges, L. Alla, E. Colomba, C. Alves Costa Silva, N. Pons, G. Baciarello, E. Le Chatelier, K. Fizazi, B. Routy, B. Escudier, L. Zitvogel, L. Derosa
Journal: Annals of Oncology (2019)
Preliminary results of a phase I study: A chimeric monoclonal anti IL-6 antibody CNTO 328 in combination with docetaxel in patients with hormone refractory prostate cancer
Authors: G. R. Hudes, D. Nanus, M. Qi, U. Prabhakar, R. Corringham, Q. Jiao, M. Eisenberger
Journal: Journal of Clinical Oncology (2007)

15521 Background: High serum levels of pro-inflammatory cytokine IL-6 may impact the progression and survival of metastatic hormone refractory prostate cancer (HRPC). CNTO328, an anti IL-6 monoclonal antibody, inhibited prostate tumor growth in several preclinical xenograft mouse models. Methods: This Phase 1, open label study evaluates the safety, pharmacokinetics (PK), and pharmacodynamics of CNTO328 at three dose levels (6mg/kg q2 weeks, 9mg/kg q3 weeks and 12mg/kg q3 weeks) in combination with docetaxel (75mg/m 2 q3 weeks) in men with metastatic HPRC. C-reactive protein (CRP), a surrogate biomarker of serum IL-6, and circulating tumor cells (CTC) are evaluated. Results: Eight patients with a median baseline PSA value of 56.8 ng/ml (range 13.6- 436.9 ng/ml) were treated in the first cohort (6 mg/kg CNTO328 q2 weeks in combination with docetaxel 75 mg/m 2 q3 weeks). At baseline, 6 patients (75%) had detectable CRP and 6 patients had detectable CTCs. The median number of CNTO328 doses and docetaxel cycles administered was 6 (CNTO328: range 3 to 11 doses; docetaxel: range 3 to 13 cycles). No first-cycle DLT was observed for this combination. Three patients discontinued treatment due to docetaxel-related grade 3 adverse events (deep vein thrombosis, hyperbilirubinemia, and nail changes) after 6, 11, and 13 cycles of docetaxel, respectively. Serum CRP decreased to below detectable levels 7 days after the first dose of CNTO328 in all patients with measurable values at baseline and remained undetectable throughout treatment. Two patients with post-treatment CTC values showed CTC reduction from 82 to1, and 127 to1, respectively. Six of 8 patients had = 50% PSA reductions and all had stable or improved bone scans and/or CT scans. PK of CNTO328 and docetaxel, alone and in combination, will be presented. Conclusions: Thus far, anti-IL6 therapy with CNTO328 at 6mg/kg q2 weeks in combination with docetaxel 75mg/m 2 q3 week has been feasible and tolerable. Complete suppression of CRP and PSA reduction provide evidence of biological and anti-tumor activity of this approach and support further testing. [Table: see text]
The importance of primary surgery in patients with de novo stage IV BC surviving at least 5 years: Protocol MF07-01 randomized clinical trial
Authors: V. Ozmen, S. Ozbas, H. Karanlik, M. Muslumanoglu, A. Igci, Z. Canturk, Z. Utkan, C. Ozaslan, T. Evrensel, C. Uras, E. Aksaz, A. Soyder, U.M. Ugurlu, C. Col, N. Cabioglu, B. Bozkurt, A. Uzunkoy, E. Sezgin, G. Gurleyik, A. Soran
Journal: Annals of Oncology (2019)
Abstract 522: Enhanced Abdominal Aortic Aneurysm (AAA) Formation in Procarboxypeptidase B (pCPB)-Deficient Mice
Authors: Maureen M Tedesco, Eiketsu Sho, Toshihiko Nishimura, Shadi Sharif, Xiaoyan Du, Ronald L Dalman, Lawrence L Leung
Journal: Circulation (2008)
Trends and Racial Disparities of Palliative Care Use among Hospitalized Patients with ESKD on Dialysis
Authors: Yumeng Wen, Changchuan Jiang, Holly M. Koncicki, Carol R. Horowitz, Richard S. Cooper, Aparna Saha, Steven G. Coca, Girish N. Nadkarni, Lili Chan
Journal: Journal of the American Society of Nephrology (2019)

Significance Statement Studies have shown significant racial and ethnic disparities in the end-of-life care received by dialysis patients with ESKD in the United States, but little is known about disparity in the palliative care services received by such patients in the inpatient setting. This retrospective cohort study of 5,230,865 hospitalizations of patients on dialysis found that, despite a significant increase in use of palliative care services from 2006 through 2014, such services remained underused. Black and Hispanic patients were less likely than white patients to receive palliative care services in the hospital, disparities that persisted in all hospital subtypes, including hospitals with a high proportion of minority patients. These results complement previous findings and highlight the importance of further investigation of systemic issues contributing to barriers and racial disparities in palliative care use. Background Study findings show that although palliative care decreases symptom burden, it is still underused in patients with ESKD. Little is known about disparity in use of palliative care services in such patients in the inpatient setting. Methods To investigate the use of palliative care consultation in patients with ESKD in the inpatient setting, we conducted a retrospective cohort study using the National Inpatient Sample from 2006 to 2014 to identify admitted patients with ESKD requiring maintenance dialysis. We compared palliative care use among minority groups (black, Hispanic, and Asian) and white patients, adjusting for patient and hospital variables. Results We identified 5,230,865 hospitalizations of such patients from 2006 through 2014, of which 76,659 (1.5%) involved palliative care. The palliative care referral rate increased significantly, from 0.24% in 2006 to 2.70% in 2014 ( P &lt;0.01). Black and Hispanic patients were significantly less likely than white patients to receive palliative care services (adjusted odds ratio [aOR], 0.72; 95% confidence interval [95% CI], 0.61 to 0.84, P &lt;0.01 for blacks and aOR, 0.46; 95% CI, 0.30 to 0.68, P &lt;0.01 for Hispanics). These disparities spanned across all hospital subtypes, including those with higher proportions of minorities. Minority patients with lower socioeconomic status (lower level of income and nonprivate health insurance) were also less likely to receive palliative care. Conclusions Despite a clear increase during the study period in provision of palliative care for inpatients with ESKD, significant racial disparities occurred and persisted across all hospital subtypes. Further investigation into causes of racial and ethnic disparities is necessary to improve access to palliative care services for the vulnerable ESKD population.
The role of PD-L1 expression as a predictive biomarker in advanced renal cell carcinoma: A meta-analysis of randomized clinical trials
Authors: A. Carretero-Gonzalez, I. Martín Sobrino, I. Sáez Sanz, D. Castellano Gauna, G.A. De Velasco Oria de Rueda
Journal: Annals of Oncology (2019)
Myeloid derived suppressor cells but not regulatory T cells are associated with adaptive immunity and clinical outcomes in anal squamous cell carcinoma
Authors: C. Borg, L. Spehner, M. Kroemer, S. Kim, M. Jary, A. Vienot, E. Klajer, M. Ramseyer, O. Adotevi, Y. Godet, T. Andre, B. Buecher, E. Francois, R. Loyon
Journal: Annals of Oncology (2019)
The prognostic impact of monocyte to lymphocyte ratio (MLR) in advanced epithelial ovarian cancer (EOC)
Authors: M Cucurull Salamero, I ruel Te García, A.J. Arroyo, B. Pardo, M. Gil, J.M. Piulats, H. Pla, C. Fina, M P Barretina Ginesta, L. Angelats, E Felip Falgas, C Erasun Lecuona, J J García Mosquera, S Martinez Román, E. Carballas, J. Hernandez, A. Esteve, M. Romeo
Journal: Annals of Oncology (2019)
Abstract MP05: Genetic Predisposition to Obesity and Healthful Plant-Based Diet in Risks of Hypertension and Cardiovascular Disease: Gene-Diet Interaction Analyses in the UK Biobank
Authors: Yoriko Heianza, Tao Zhou, Dianjianyi Sun, Lu Qi
Journal: Circulation (2019)

Introduction: Plant-based diets include beneficial nutrients for the prevention of obesity and cardiovascular disease (CVD). No study has assessed interactions between a new healthful plant-based diet index (hPDI) and genetic predisposition to obesity in relation to adiposity and its related metabolic abnormalities. Hypothesis: We assessed the hypothesis that adherence to healthy plant-based diets would modify the genetic risk of obesity, and people at genetically higher risk of obesity would be more susceptible to the healthy diets for improving obesity and cardiovascular health. Methods: This study included 160184 participants initially free of CVD (myocardial infarction or stroke), diabetes, and cancer. We calculated the hPDI in which healthy plant foods received positive scores and the other foods received negative scores based on previous studies. A genetic risk score (GRS) of obesity was created based on 75 SNPs for BMI. Outcome measures included differences in BMI and mean arterial blood pressure (MAB), untreated hypertension (systolic blood pressure ≥130 mmHg, diastolic blood pressure ≥80 mmHg without antihypertensive medication use), and the 5-year incidence of CVD. Results: Higher hPDI was related to lower risks of obesity and untreated hypertension among the total study participants. We found a significant interaction between GRS and hPDI for BMI (Pinteraction &lt;0.0001) (Fig. panel A). For people at genetically high risk, higher hPDI was more strongly associated with lower BMI levels. The significant GRS-hPDI interaction was also found for MAB levels and the risk of untreated hypertension (panels B and C). The effect of GRS-hPDI interaction was also related to the subsequent risk of CVD (Fig. panel D). Conclusions: Adherence to the healthy plant-based dietary pattern significantly attenuated genetic association with obesity. People at genetically higher risk of obesity may be more susceptible to benefits of healthy plant-based diets in improving adiposity and cardiovascular health.
Nab-paclitaxel (Nab) plus gemcitabine (G) is more effective than G alone in locally advanced, unresectable pancreatic cancer (LAUPC): The GAP trial, a GISCAD phase II comparative randomized trial
Authors: S. Cascinu, R. Berardi, R. Bianco, D. Bilancia, A. Zaniboni, D. Ferrari, S. Mosconi, A. Spallanzani, L. Cavanna, S. Leo, F. Negri, G.D. Beretta, A. Sobrero, M. Banzi, A. Morabito, A. Bittoni, R. Marciano, D. Ferrara, S. Noventa, M.C. Piccirillo
Journal: Annals of Oncology (2019)
Multicenter phase I trial of a DNA vaccine encoding the androgen receptor ligand binding domain (pTVG-AR, MVI-118) in patients with metastatic prostate cancer
Authors: D.G. McNeel, B. Saraiya, M. Schweizer, J. Eickhoff, E. Wargowski, R. Lesniewski, B. Olson, C. Kyriakopoulos
Journal: Annals of Oncology (2019)
Diffuse large B cell lymphoma in the elderly. A retrospective analysis of standard versus alternative treatments
Authors: I.D. Sillero, N. lopetegui lia, P. Gonzalez, L.F. Sánchez-Cousido, M. López Flores, M. Rojas Piedra, S. Medina, A. López González, M. Pedraza Lorenzo, Á Rodríguez Sánchez, B. Nieto Mangudo, C. Castañón González, L. De Sande, P. Diz Tain, A. García-Palomo, S. Fernandez, F. Ramos, F. Escalante
Journal: Annals of Oncology (2019)
Infant formula, the environment, and <i>The BMJ</i>
Authors: Fiona Godlee
Journal: BMJ (2019)

When we stopped taking advertisements for breast milk substitutes earlier this year, it was because of the many ways in which the producers of infant formula have undermined breastfeeding around the world (doi:10.1136/bmj.l1200). We hadn’t considered another compelling reason: the damage that infant formula does to the environment. This week Naomi Joffe and colleagues itemise how formula milk contributes to ecological degradation and climate change (doi:10.1136/bmj.l5646).

As well as the carbon, methane, and water footprints, there are the discarded cans going to landfill, the paper, postage, and plastic, the …
Abstract 2198: Left Ventricular Asynchrony Contributes to Symptoms in Patients with Hypertrophic Cardiomyopathy
Authors: Dejan Maras, Robin Chung, Alison M Duncan, Christine Thorp, Wei Li, Michael Y Henein
Journal: Circulation (2008)

Objective: Hypertrophic cadiomyopathy (HCM) results in exertional symptoms due to limited cardiac output that improve after removal of the left ventricular outflow tract (LVOT) obstruction. We aimed to assess the effect of pharmacological stress on LV asynchrony in a group of patients with HCM limited by exertional breathlessness. Methods: We studied 17 normal controls (aged 58 ± 12 years) and 37 HCM patients (aged 54 ± 15 years, 13 female) with septal thickness &gt;15 mm using Doppler echocardiography, at rest and at peak dobutamine stress. Stress end points were symptoms, &gt;20 mmHg drop in systolic blood pressure, arrhythmia, or maximum dobutamine infusion of 40μcg/kg/min. Ventricular asynchrony was assessed by total isovolumic time and Tei index. Results: At rest: LVOT velocity was raised in HCM patients compared to normals (2.0 ± 0.9 v 1.0 ± 2.4, p&lt;0.001, respectively). Total isovolumic time was not significantly different between HCM and normals (10.6 ± 4.4 v 12 ± 2 s/min, respectively), and Tei index was not significantly different between HCM and normals (0.6 ± 0.1 v 0.54 ± 0.2, p=NS, respectively). At peak stress: LVOT velocities increased in HCM compared to normals (4.3 ± 1.7 v 1.7 ± 1.0 m/s, p&lt;0.005, respectively) due to systolic anterior movement of the mitral valve. Total IVT decreased in both HCM and normals (6.3 ± 5.2 v 5 ± 2 s/min,p&lt;0.005, compared to resting values, respectively) as did Tei index (0.24 ± 0.04 v 0.23 ± 0.06, p&lt;0.01, respectively). Total LV filling time decreased in HCM but increased in normals (HCM rest v stress: 29.6 ± 4.5 v 27.5 ± 4.5 s/min, p&lt; 0.05; normals rest v stress 28 ± 4 v 33 ± 3 s/min, p&lt;0.005). QRS duration increased with stress in HCM patients (rest v stress: 103 ± 28 v 110 ± 26 ms, p&lt;0.01), but decreased in normals (rest v stress. 91 ± 9 v 87 ± 8 ms, p=NS). Conclusion: Stress results in LV outflow tract obstruction in HCM patients, resulting in known pathophysiological consequences– mitral regurgitation and raised left atrial pressure. In addition, increased ventricular asynchrony compromises filling time. The historical benefit from DDD pacing in this condition may be explained on the basis of LV resynchronisation rather than simply drop in outflow tract gradient.
Still dying in plain sight: missed and misclassified deaths due to tuberculosis in hospitals
Authors: Byron William Patrick Reeve, Rosella Centis, Grant Theron
Journal: European Respiratory Journal (2019)

<b>The study reported by Garcia-Basterio and co-workers has used Xpert MTB/RIF Ultra in cadavers for the first time, to improve detection of TB cases that would have ordinarily been missed by histology or clinical examination.</b>http://bit.ly/2P9Zpyz
Classification of esthesioneuroblastoma (ENB) based on chromosome (chr) arm gain and loss (CNA) in the setting of a hypomutated genomic landscape
Authors: R. Madison, D.C. Pavlick, J.M. Johnson, S. Khan, J. Lee, J.S. Ross, V.A. Miller, B.M. Alexander, J. Chung, A.B. Schrock, S.M. Ali
Journal: Annals of Oncology (2019)
Efficacy and safety of oral poly (ADP-ribose) polymerase inhibitor fluzoparib in patients with BRCA1/2 mutations and platinum sensitive recurrent ovarian cancer
Authors: N. Li, L. Wu, Y. Zhang, J. Liu, Q. Zhou, J. Zhu, R. Yin, L. Wang, G. Li, X. Wu, H. Pan, S. Yao, Q. Wu, K. Gu, H. Zhang, X. Wan, R. An, J. Zou, Q. Wang
Journal: Annals of Oncology (2019)
Is High-Dose Vitamin C Beneficial for Patients With Sepsis?
Authors: Emily B. Brant, Derek C. Angus
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors
Authors: Francesco Facchinetti, Antoine Hollebecque, Rastislav Bahleda, Yohann Loriot, Ken A. Olaussen, Christophe Massard, Luc Friboulet
Journal: Clinical Cancer Research (2019)

Abstract Precision oncology relies on the identification of molecular alterations, responsible for tumor initiation and growth, which are suitable targets of specific inhibitors. The development of FGFR inhibitors represents an edifying example of the rapid evolution in the field of targeted oncology, with 10 different FGFR tyrosine kinase inhibitors actually under clinical investigation. In parallel, the discovery of FGFR activating molecular alterations (mainly FGFR3 mutations and FGFR2 fusions) across many tumor types, especially urothelial carcinomas and intrahepatic cholangiocarcinomas, widens the selection of patients that might benefit from selective FGFR inhibitors. The ongoing concomitant clinical evaluation of selective FGFR inhibitors in molecularly selected solid tumors brings new hopes for patients with metastatic cancer, for tumors so far excluded from molecularly guided treatments. Matching molecularly selected tumors with selective FGFR inhibitors has indeed led to promising results in phase I and II trials, justifying their registration to be expected in a near future, such as the recent accelerated approval of erdafitinib granted by the FDA for urothelial cancer. Widening our knowledge of the activity, efficacy, and toxicities relative to the selective FGFR tyrosine kinase inhibitors under clinical investigation, according to the exact FGFR molecular alteration, will be crucial to determine the optimal therapeutic strategy for patients suffering from FGFR-driven tumors. Similarly, identifying with appropriate molecular diagnostic, every single tumor harboring targetable FGFR alterations will be of utmost importance to attain the best outcomes for patients with FGFR-driven cancer.
PB1972 RIBOCICLIB INDUCES MACROCYTOSIS IN THERAPEUTIC DOSES: CHARACTERIZATION OF OUTCOME
Authors: S. Alves, S. Alves
Journal: HemaSphere (2019)

Background: Ribociclib is a small molecule that selectively inhibits cyclin‐dependent kinases 4 and 6, blocking the phosphorylation of retinoblastoma protein and inducing of G1 phase arrest hence having an important role in the regulation and prevention of cell‐cycle progression. The project OncoDynamics aims to explore possible correlations between therapeutic doses of ribociclib for treatment of breast cancer and other therapies with several analytic biomarkers and clinical data. Adverse events of CDK 4/6 inhibitors are mostly hematologic being neutropenia the most frequent followed by anemia and thrombocytopenia as it is the case of palbociclib which has been recently described as associated with macrocytic, dysplastic anemia. Aims: This study aims to characterize the outcome of macrocytosis evident in our patients treated with ribociclib in therapeutic doses for treatment of breast cancer. Methods: This study is integrated in the OncoDynamics project and is a prospective, unicentric cohort study with patients treated for metastatic breast cancer with ribociclib plus letrozole, each patient registered as digital case report form and evaluated data of mean corpuscular volume (MCV), hemoglobin (Hg) and red cell distribution width (RCDW) for descriptive analyses. Results: Of the 7 patients with breast cancer treated with ribociclib (14,8%) with a follow up period ranging from 3 to 18 months, 4 patients (57,1%) had a sustained rise of the mean corpuscular volume (MCV &gt; 97 fL), Hg ranging from 8,8 to 13,5 g/dL and RCDW from 12,7 to 20,9 CV%. Summary/Conclusion: We found this macrocytosis to be related to the treatment with ribociclib in therapeutic doses and in literature the correlation between CDK 4/6 inhibitors and macrocytosis has been described in relation to palbociclib. Clinical evolution of these patients is under evaluation. We aim to extend this study and to explore the inherent mechanism of action of ribociclib regarding anemia and macrocytosis.